<?xml version='1.0' encoding='utf8'?>
<text id="AMALGUM_academic_copolymers" title="Polycaprolactone-Based Mimetic Antimicrobial Peptide Copolymers Vesicles as an Effective Drug-Carrier for Cancer Therapy" shortTitle="copolymers" author="Yusheng Qian, Xinyu Zhou, Jing He, Chuncai Zhou" type="academic" dateCollected="2019-11-03" sourceURL="https://www.mdpi.com/2073-4360/11/11/1783/htm" speakerList="none" speakerCount="0">
<head>
<s type="frag">
1.	LS	1.
Introduction	NN	introduction
</s>
</head>
<p>
<s type="decl">
Cancer	NN	cancer
is	VBZ	be
one	CD	one
of	IN	of
the	DT	the
most	RBS	most
important	JJ	important
and	CC	and
deadly	JJ	deadly
diseases	NNS	disease
worldwide	RB	worldwide
.	.	.
</s>
<s type="decl">
Reports	NNS	report
from	IN	from
the	DT	the
World	NNP	World
Health	NNP	Health
Organization	NNP	Organization
show	VBP	show
that	IN	that
almost	RB	almost
1	CD	1
in	IN	in
6	CD	6
deaths	NNS	death
worldwide	RB	worldwide
in	IN	in
<date when="2018">
2018	CD	2018
</date>
were	VBD	be
due	JJ	due
to	IN	to
cancer	NN	cancer
.	.	.
</s>
<s type="decl">
Chemotherapy	NN	chemotherapy
is	VBZ	be
a	DT	a
common	JJ	common
approach	NN	approach
for	IN	for
cancer	NN	cancer
treatment	NN	treatment
;	:	;
it	PRP	it
uses	VBZ	use
drugs	NNS	drug
to	TO	to
kill	VB	kill
cancer	NN	cancer
cells	NNS	cell
.	.	.
</s>
<s type="decl">
However	RB	however
,	,	,
various	JJ	various
limitations	NNS	limitation
affect	VBP	affect
the	DT	the
efficiency	NN	efficiency
of	IN	of
chemotherapy	NN	chemotherapy
.	.	.
</s>
<s type="decl">
For	IN	for
example	NN	example
,	,	,
most	JJS	most
chemotherapeutics	NNS	chemotherapeutics
possess	VBP	possess
poor	JJ	poor
aqueous	JJ	aqueous
solubility	NN	solubility
,	,	,
harm	VBP	harm
normal	JJ	normal
cell	NN	cell
toxicity	NN	toxicity
due	JJ	due
to	IN	to
the	DT	the
lack	NN	lack
of	IN	of
selectivity	NN	selectivity
,	,	,
and	CC	and
cause	VBP	cause
multidrug	JJ	multidrug
resistance	NN	resistance
.	.	.
</s>
<s type="decl">
To	TO	to
handle	VB	handle
these	DT	this
shortcomings	NNS	shortcoming
,	,	,
researchers	NNS	researcher
have	VBP	have
proposed	VBN	propose
nano-particles	NNS	nano-particle
as	IN	as
novel	JJ	novel
drug	NN	drug
carriers	NNS	carry
to	TO	to
help	VB	help
patients	NNS	patient
cope	VB	cope
with	IN	with
cancer	NN	cancer
.	.	.
</s>
<s type="decl">
Nanoparticles	NNS	nanoparticle
,	,	,
like	IN	like
vesicles	NNS	vesicle
,	,	,
nanotubes	NNS	nanotube
,	,	,
micelles	NNS	micelle
,	,	,
nanofibers	NNS	nanofiber
,	,	,
and	CC	and
nanosheet	NN	nanosheet
are	VBP	be
typically	RB	typically
commonly	RB	commonly
formed	VBN	form
by	IN	by
amphiphilic	JJ	amphiphilic
copolymers	NNS	copolymer
via	IN	via
self-assembly	NN	self-assembly
.	.	.
</s>
<s type="sub">
Nanoparticles	NNS	nanoparticle
can	MD	can
encapsulate	VB	encapsulate
drugs	NNS	drug
via	IN	via
physical	JJ	physical
entrapment	NN	entrapment
or	CC	or
solubilization	NN	solubilization
to	TO	to
achieve	VB	achieve
various	JJ	various
advantages	NNS	advantage
,	,	,
including	VBG	include
controlled	VBN	control
drug	NN	drug
release	NN	release
,	,	,
decreased	VBN	decrease
cytotoxicity	NN	cytotoxicity
,	,	,
increased	VBN	increase
aqueous	JJ	aqueous
solubility	NN	solubility
,	,	,
and	CC	and
targeted	VBN	target
action	NN	action
site	NN	site
.	.	.
</s>
<s type="decl">
Thus	RB	thus
,	,	,
nanoparticles	NNS	nanoparticle
have	VBP	have
opened	VBN	open
the	DT	the
door	NN	door
for	IN	for
developing	VBG	develop
effective	JJ	effective
drug	NN	drug
delivery	NN	delivery
schemes	NNS	scheme
and	CC	and
have	VBP	have
shown	VBN	show
substantial	JJ	substantial
potential	NN	potential
for	IN	for
applications	NNS	application
in	IN	in
life-threatening	JJ	life-threatening
disease	NN	disease
treatments	NNS	treatment
,	,	,
such	JJ	such
as	IN	as
cancer	NN	cancer
therapy	NN	therapy
.	.	.
</s>
</p>
<p>
<s type="decl">
Chemotherapy	NN	chemotherapy
usually	RB	usually
causes	VBZ	cause
a	DT	a
decline	NN	decline
in	IN	in
immunity	NN	immunity
,	,	,
causing	VBG	cause
cancer	NN	cancer
patients	NNS	patient
to	TO	to
suffer	VB	suffer
from	IN	from
bacterial	JJ	bacterial
infection	NN	infection
or	CC	or
threatening	VBG	threaten
their	PRP$	their
lives	NNS	life
.	.	.
</s>
<s type="decl">
Therefore	RB	therefore
,	,	,
avoiding	VBG	avoid
bacterial	JJ	bacterial
infection	NN	infection
is	VBZ	be
essential	JJ	essential
during	IN	during
cancer	NN	cancer
therapy	NN	therapy
.	.	.
</s>
<s type="decl">
As	IN	as
a	DT	a
kind	NN	kind
of	IN	of
novel	JJ	novel
antibacterial	JJ	antibacterial
agent	NN	agent
,	,	,
antimicrobial	JJ	antimicrobial
peptides	NNS	peptide
(	-LRB-	(
AMPs	NNS	amp
)	-RRB-	)
have	VBP	have
gained	VBN	gain
increasing	VBG	increase
attention	NN	attention
over	IN	over
the	DT	the
past	JJ	past
few	JJ	few
decades	NNS	decade
.	.	.
</s>
<s type="decl">
AMPs	NNS	amp
exhibit	VBP	exhibit
excellent	JJ	excellent
antibacterial	JJ	antibacterial
capability	NN	capability
and	CC	and
a	DT	a
unique	JJ	unique
antibacterial	JJ	antibacterial
mechanism	NN	mechanism
.	.	.
</s>
<s type="decl">
AMPs	NNS	amp
achieve	VBP	achieve
their	PRP$	their
bactericidal	JJ	bactericidal
effect	NN	effect
by	IN	by
physical	JJ	physical
disruption	NN	disruption
of	IN	of
bacterial	JJ	bacterial
membranes	NNS	membrane
;	:	;
however	RB	however
,	,	,
inducing	VBG	induce
bacterial	JJ	bacterial
drug	NN	drug
resistance	NN	resistance
presents	VBZ	present
difficulty	NN	difficulty
.	.	.
</s>
<s type="decl">
Research	NN	research
illustrates	VBZ	illustrate
that	IN	that
such	PDT	such
a	DT	a
unique	JJ	unique
antibacterial	JJ	antibacterial
mechanism	NN	mechanism
is	VBZ	be
relevant	JJ	relevant
to	IN	to
specific	JJ	specific
AMP	NNP	AMP
structures	NNS	structure
,	,	,
including	VBG	include
cationic	JJ	cationic
moieties	NNS	moiety
such	JJ	such
as	IN	as
lysine	NN	lysine
and	CC	and
hydrophobic	JJ	hydrophobic
moieties	NNS	moiety
such	JJ	such
as	IN	as
phenylalanine	NN	phenylalanine
.	.	.
</s>
<s type="decl">
Lots	NNS	lot
of	IN	of
AMPs	NNS	amp
are	VBP	be
amphiphilic	JJ	amphiphilic
peptides	NNS	peptide
,	,	,
namely	RB	namely
,	,	,
they	PRP	they
are	VBP	be
composed	VBN	compose
of	IN	of
hydrophobic	JJ	hydrophobic
and	CC	and
hydrophilic	JJ	hydrophilic
residues	NNS	residue
.	.	.
</s>
<s type="decl">
AMP-nanoparticles	NNS	AMP-nanoparticle
can	MD	can
be	VB	be
prepared	VBN	prepare
in	IN	in
an	DT	a
aqueous	JJ	aqueous
solution	NN	solution
through	IN	through
self-assembly	NN	self-assembly
of	IN	of
these	DT	this
AMPs	NNS	amp
.	.	.
</s>
<s type="decl">
AMP	NNP	AMP
assemblies	NNS	assembly
are	VBP	be
ideal	JJ	ideal
drug	NN	drug
delivery	NN	delivery
systems	NNS	system
exhibiting	VBG	exhibit
both	CC	both
drug	NN	drug
release	NN	release
and	CC	and
antibacterial	JJ	antibacterial
capabilities	NNS	capability
during	IN	during
cancer	NN	cancer
treatment	NN	treatment
.	.	.
</s>
<s type="decl">
Our	PRP$	our
group	NN	group
has	VBZ	have
reported	VBN	report
several	JJ	several
amphiphilic	JJ	amphiphilic
block	NN	block
AMPs	NNS	amp
containing	VBG	contain
lysine	NN	lysine
and	CC	and
phenylalanine	NN	phenylalanine
.	.	.
</s>
<s type="decl">
These	DT	this
AMPs	NNS	amp
exhibit	VBP	exhibit
high	JJ	high
bactericidal	JJ	bactericidal
efficiency	NN	efficiency
and	CC	and
low	JJ	low
cytotoxicity	NN	cytotoxicity
.	.	.
</s>
<s type="decl">
Vesicles	NNS	vesicle
formed	VBN	form
by	IN	by
these	DT	this
AMPs	NNS	amp
have	VBP	have
good	JJ	good
performance	NN	performance
when	WRB	when
carrying	VBG	carry
drugs	NNS	drug
.	.	.
</s>
</p>
<p>
<s type="decl">
Motivated	VBN	motivate
by	IN	by
the	DT	the
excellent	JJ	excellent
properties	NNS	property
and	CC	and
promising	JJ	promising
applications	NNS	application
of	IN	of
AMP	NNP	AMP
nanoparticles	NNS	nanoparticle
,	,	,
synthetic	JJ	synthetic
amphiphilic	JJ	amphiphilic
AMP	NNP	AMP
–	SYM	-
mimetic	JJ	mimetic
polymers	NNS	polymer
are	VBP	be
proposed	VBN	propose
.	.	.
</s>
<s type="decl">
These	DT	this
amphiphilic	JJ	amphiphilic
copolymers	NNS	copolymer
stimulate	VBP	stimulate
the	DT	the
structural	JJ	structural
features	NNS	feature
of	IN	of
AMPs	NNS	amp
,	,	,
that	RB	that
is	VBZ	be
,	,	,
cationic	JJ	cationic
and	CC	and
hydrophobic	JJ	hydrophobic
moieties	NNS	moiety
.	.	.
</s>
<s type="decl">
Amphiphilic	JJ	Amphiphilic
copolymers	NNS	copolymer
not	RB	not
only	RB	only
possess	VBP	possess
good	JJ	good
properties	NNS	property
,	,	,
such	JJ	such
as	IN	as
a	DT	a
unique	JJ	unique
bactericidal	JJ	bactericidal
mechanism	NN	mechanism
,	,	,
the	DT	the
capability	NN	capability
for	IN	for
self-assembly	NN	self-assembly
into	IN	into
nanoparticles	NNS	nanoparticle
that	WDT	that
are	VBP	be
similar	JJ	similar
to	IN	to
those	DT	this
of	IN	of
natural	JJ	natural
AMPs	NNS	amp
,	,	,
but	CC	but
also	RB	also
show	VBP	show
more	RBR	more
convenient	JJ	convenient
synthesis	NN	synthesis
strategy	NN	strategy
than	IN	than
natural	JJ	natural
AMPs	NNS	amp
.	.	.
</s>
<s type="decl">
In	IN	in
previous	JJ	previous
work	NN	work
,	,	,
Zhou	NNP	Zhou
et	FW	et
al.	FW	al.
have	VBP	have
reported	VBN	report
the	DT	the
minimal	JJ	minimal
inhibition	NN	inhibition
concentration	NN	concentration
(	-LRB-	(
MIC	NNP	MIC
)	-RRB-	)
of	IN	of
amphiphilic	JJ	amphiphilic
copolymers	NNS	copolymer
was	VBD	be
less	JJR	less
than	IN	than
32	CD	32
μg/mL	NN	μg/mL
against	IN	against
both	CC	both
Gram-negative	JJ	Gram-negative
and	CC	and
Gram-positive	JJ	Gram-positive
bacteria	NNS	bacteria
.	.	.
</s>
<s type="decl">
The	DT	the
broad	JJ	broad
antibacterial	JJ	antibacterial
capability	NN	capability
has	VBZ	have
been	VBN	be
proved	VBN	prove
,	,	,
which	WDT	which
will	MD	will
play	VB	play
a	DT	a
vital	JJ	vital
role	NN	role
in	IN	in
cancer	NN	cancer
therapy	NN	therapy
.	.	.
</s>
</p>
<p>
<s type="frag">
In	IN	in
our	PRP$	our
previous	JJ	previous
work	NN	work
,	,	,
a	DT	a
series	NN	series
of	IN	of
amphiphilic	JJ	amphiphilic
mimicked	VBN	mimick
AMP	NNP	AMP
copolymers	NNS	copolymer
,	,	,
PCL16-	NNP	PCL16-
<hi rend="italic">
b	NN	b
</hi>
-Kn	NN	-Kn
,	,	,
which	WDT	which
can	MD	can
inhibit	VB	inhibit
both	CC	both
Gram-negative	JJ	Gram-negative
and	CC	and
Gram-positive	JJ	Gram-positive
bacteria	NNS	bacteria
.	.	.
</s>
<s type="decl">
In	IN	in
the	DT	the
present	JJ	present
work	NN	work
,	,	,
we	PRP	we
studied	VBD	study
the	DT	the
self-assembling	JJ	self-assembling
behavior	NN	behavior
of	IN	of
these	DT	this
block	NN	block
copolymers	NNS	copolymer
in	IN	in
aqueous	JJ	aqueous
solutions	NNS	solution
.	.	.
</s>
<s type="decl">
The	DT	the
morphologies	NNS	morphology
and	CC	and
sizes	NNS	size
of	IN	of
nanoparticles	NNS	nanoparticle
were	VBD	be
characterized	VBN	characterize
by	IN	by
transmission	NN	transmission
electron	NN	electron
microscopy	NN	microscopy
(	-LRB-	(
TEM	NNP	TEM
)	-RRB-	)
and	CC	and
dynamic	JJ	dynamic
light	NN	light
scattering	NN	scattering
(	-LRB-	(
DLS	NNP	DLS
)	-RRB-	)
,	,	,
respectively	RB	respectively
.	.	.
</s>
<s type="decl">
Critical	JJ	Critical
vesiculation	NN	vesiculation
concentrations	NNS	concentration
(	-LRB-	(
CVCs	NNPS	CVC
)	-RRB-	)
were	VBD	be
also	RB	also
studied	VBN	study
.	.	.
</s>
<s type="decl">
Drug	NN	drug
delivery	NN	delivery
potential	NN	potential
was	VBD	be
investigated	VBN	investigate
by	IN	by
in	IN	in
vitro	NN	vitro
and	CC	and
intracellular	JJ	intracellular
doxorubicin	NN	doxorubicin
(	-LRB-	(
DOX)-release	NNP	DOX)-release
experiments	NNS	experiment
.	.	.
</s>
<s type="sub">
Based	VBN	base
on	IN	on
the	DT	the
results	NNS	result
,	,	,
amphiphilic	JJ	amphiphilic
diblock	NN	diblock
copolymers	NNS	copolymer
PCL16-	NN	PCL16-
<hi rend="italic">
b	NN	b
</hi>
-Kn	NN	-Kn
could	MD	could
serve	VB	serve
as	IN	as
efficient	JJ	efficient
drug	NN	drug
carriers	NNS	carry
for	IN	for
cancer	NN	cancer
treatment	NN	treatment
.	.	.
</s>
<s type="frag">
Given	VBN	give
the	DT	the
excellent	JJ	excellent
antibacterial	JJ	antibacterial
properties	NNS	property
and	CC	and
low	JJ	low
cytotoxicity	NN	cytotoxicity
of	IN	of
PCL16-	NNP	PCL16-
<hi rend="italic">
b	NN	b
</hi>
-Kn	.	-Kn
</s>
<s type="sub">
in	IN	in
previous	JJ	previous
works	NNS	work
,	,	,
such	JJ	such
diblock	NN	diblock
copolymer	NN	copolymer
nanoparticles	NNS	nanoparticle
can	MD	can
be	VB	be
ideal	JJ	ideal
“	``	''
armed	JJ	armed
”	''	''
drug	NN	drug
delivery	NN	delivery
systems	NNS	system
for	IN	for
applications	NNS	application
in	IN	in
nanomedical	JJ	nanomedical
fields	NNS	field
.	.	.
</s>
</p>
</text>